PloS one

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

JAAPA

reproduction in domestic animals = zuchthygiene

[1] Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.

[2] Genomic characterization of the complete terpene synthase gene family from Cannabis sativa.

[3] Treating patients with opioid use disorder.

[4] Proceedings of the 23 Annual Conference of the European Society for Domestic Animal Reproduction (ESDAR), St Petersburg, Russia, 19-22 September 2019.

[5] Incidence and Transmission Patterns of Acute Hepatitis C in the United States, 1982-2006

[6] Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus

[7] The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007

[8] Performance of premarket rapid hepatitis C virus antibody assays in 4 national human immunodeficiency virus behavioral surveillance system sites

[9] Family physicians' knowledge and screening of chronic hepatitis and liver cancer

[10] Telaprevir for previously untreated chronic hepatitis C virus infection

[11] Boceprevir for untreated chronic HCV genotype 1 infection

[12] The Institute of Medicine report on viral hepatitis: a call to action

[13] Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States

[14] The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States

[15] The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings

[16] The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

[17] Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma

[18] seropositivity of hepatitis b and c among syrian multitransfused patients with hemoglobinopathy

[19] The Impact of Markers of HIV Infection on Change in Liver Stiffness in People With HIV and Hepatitis C Virus Co-infection After Treatment and Cure of Hepatitis C

[20] Hepatitis C Virus-Infected Patients Receiving Opioid Substitution Therapy Experience Improvement in Patient-Reported Outcomes Following Treatment With Interferon-Free Regimens

[21] Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals

[22] [Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]

[23] Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis

[24] Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial

[25] Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

[26] Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial

[27] Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis

[28] A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C

[29] An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens

[30] Acute hepatitis B in patients with or without underlying chronic HCV infection

[31] Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis

[32] Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies

[33] Regression of Hodgkin lymphoma in response to antiviral therapy for hepatitis C virus infection

[34] Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?

[35] Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis

[36] Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C

[37] Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents

[38] Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

[39] Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection

[40] Sofosbuvir for previously untreated chronic hepatitis C infection

[41] Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada

[42] A severe hepatitis flare in an HBV-HCV coinfected patient during combination therapy with alpha-interferon and ribavirin

[43] Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

[44] Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.

[45] How expensive may drugs be? The example of hepatitis C drugs

[46] Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach.

[47] Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

[48] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[49] Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

[50] Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

[51] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[52] Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

[53] Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

[54] Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

[55] Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

[56] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

[57] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

[58] Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

[59] Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

[60] Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

[61] Conceptual framework for outcomes research studies of hepatitis C: an analytical review

[62] Influence of host resistance on viral adaptation: hepatitis C virus as a case study

[63] Approaches to hepatitis C treatment and cure using NS5A inhibitors

[64] Current treatment of choice for chronic hepatitis C infection

[65] New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

[66] Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

[67] Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

[68] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

[69] Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

[70] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[71] Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

[72] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

[73] Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

[74] Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

[75] Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

[76] Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

[77] Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

[78] Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

[79] Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

[80] Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

[81] Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

[82] Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

[83] Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

[84] Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

[85] Conceptual framework for outcomes research studies of hepatitis C: an analytical review

[86] Influence of host resistance on viral adaptation: hepatitis C virus as a case study

[87] Approaches to hepatitis C treatment and cure using NS5A inhibitors

[88] Current treatment of choice for chronic hepatitis C infection

[89] New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

[90] Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

[91] Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

[92] Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

[93] Effectiveness and Cost-Effectiveness of Triple Therapy with Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from the Brazilian Public Health System Perspective

[94] Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital

[95] Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia.

[96] The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015.

[97] Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: a cohort study.

[98] Real-world effectiveness and safety of Ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.

[99] Infant follow-up postdelivery from a hepatitis C viral load positive mother

[100] The new Xpert HCV viral load real-time PCR assay accurately quantifies hepatitis C virus RNA in serum and whole-blood specimens

[101] Challenging hepatitis C-infected liver transplant patients